OTCPK:CGNS.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Cognetivity Neurosciences

Executive Summary

Cognetivity Neurosciences Ltd. operates as a healthcare company.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Cognetivity Neurosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CGNS.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.7%

CGNS.F

-0.2%

US Medical Equipment

3.0%

US Market


1 Year Return

-54.5%

CGNS.F

14.8%

US Medical Equipment

15.8%

US Market

Return vs Industry: CGNS.F underperformed the US Medical Equipment industry which returned 16.8% over the past year.

Return vs Market: CGNS.F underperformed the US Market which returned 15.4% over the past year.


Shareholder returns

CGNS.FIndustryMarket
7 Day1.7%-0.2%3.0%
30 Day-11.2%8.5%6.0%
90 Day-11.2%10.7%16.4%
1 Year-54.5%-54.5%15.8%14.8%18.4%15.8%
3 Yearn/a75.5%70.7%44.8%35.4%
5 Yearn/a118.0%101.1%75.7%56.7%

Price Volatility Vs. Market

How volatile is Cognetivity Neurosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cognetivity Neurosciences undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Cognetivity Neurosciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cognetivity Neurosciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of CGNS.F's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Cognetivity Neurosciences regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Cognetivity Neurosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cognetivity Neurosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of CGNS.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Cognetivity Neurosciences's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Cognetivity Neurosciences performed over the past 5 years?

-31.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CGNS.F is currently unprofitable.

Growing Profit Margin: CGNS.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CGNS.F is unprofitable, and losses have increased over the past 5 years at a rate of 31.3% per year.

Accelerating Growth: Unable to compare CGNS.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CGNS.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.2%).


Return on Equity

High ROE: CGNS.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Cognetivity Neurosciences's financial position?


Financial Position Analysis

Short Term Liabilities: CGNS.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CGNS.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CGNS.F has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CGNS.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CGNS.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CGNS.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34.3% each year


Next Steps

Dividend

What is Cognetivity Neurosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CGNS.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CGNS.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CGNS.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CGNS.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CGNS.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average board tenure


CEO

Sina Habibi

no data

Tenure

CA$136,814

Compensation

Dr. Sina Habibi serves as Co-Founder & Chief Executive Officer at Cognetivity Neurosciences Ltd and also serves as its Director since December 21, 2017.


CEO Compensation Analysis

Compensation vs Market: Sina's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD606.98K).

Compensation vs Earnings: Insufficient data to compare Sina's compensation with company performance.


Board Members

NamePositionTenureCompensationOwnership
Sina Habibi
Co-Founderno dataCA$136.81k8.86%
CA$ 480.7k
Mark Phillips
Chief Compliance Officer & Director2.67yrsCA$45.33k0.90%
CA$ 49.1k
Chris Kalafatis
Chief Medical Officer & Director2.67yrsCA$47.84k0.72%
CA$ 39.2k
Hanspeter Spek
Member of Advisory Board2.08yrsno datano data
Keith Gibbs
Member of Advisory Board0.75yrno datano data
David Velisek
Independent Director4.67yrsno data0.20%
CA$ 10.7k
Ravinder Kang
Independent Director2.67yrsno datano data

2.7yrs

Average Tenure

58yo

Average Age

Experienced Board: CGNS.F's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.2%.


Top Shareholders

Company Information

Cognetivity Neurosciences Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cognetivity Neurosciences Ltd.
  • Ticker: CGNS.F
  • Exchange: OTCPK
  • Founded: 2015
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$7.223m
  • Listing Market Cap: CA$5.428m
  • Shares outstanding: 60.19m
  • Website: https://www.cognetivity.com

Number of Employees


Location

  • Cognetivity Neurosciences Ltd.
  • 1055 West Hastings Street
  • Suite 2250
  • Vancouver
  • British Columbia
  • V6E 2E9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CGNCNSX (Canadian National Stock Exchange)YesNew Common SharesCACADMar 2018
1UBDB (Deutsche Boerse AG)YesNew Common SharesDEEURMar 2018
CGNS.FOTCPK (Pink Sheets LLC)YesNew Common SharesUSUSDMar 2018

Biography

Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical and commercial environments for potentially ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/07 01:00
End of Day Share Price2020/08/06 00:00
Earnings2020/04/30
Annual Earnings2020/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.